APG-2575 for mild to moderate lupus
Treatments studied
Part of Immune system & allergy clinical trials.
This trial tests an experimental drug called APG-2575 for people with mild to moderate lupus. It aims to see if the drug can help control lupus activity and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with lupus for at least 6 months.
- Your lupus treatments (medications and doses) have been stable for the past 28 days or more.
- Your lupus disease activity score is between 4 and 12 (mild to moderate activity).
- You do not have severe lupus or another major autoimmune condition.
- You do not have serious, uncontrolled health problems in other organs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called CLN-978, given as a shot under the skin, that targets a protein on certain immune cells (B cells) to try to calm overactive immune activity in lupus. The goal is to see if it can reduce lupus symptoms for people whose disease has not been controlled by other treatments.
This trial tests a new oral medication called D-2570 for people with active systemic lupus erythematosus (SLE). It aims to see if the drug can help control lupus symptoms while you continue your current stable treatments.
This trial tests a new medicine called CC312 for people with moderate to severe lupus (SLE) that hasn't improved with standard treatments. The goal is to see if it is safe and can help control the disease.
This trial tests a new treatment called CM355 for people with systemic lupus erythematosus (SLE), a chronic autoimmune disease. It aims to see if the drug can help control disease activity in patients whose lupus is not well managed by current therapies.
This study tests a new injectable medicine (SG301) for people with lupus (SLE) whose current treatments are not working well enough or cause side effects. It aims to see if this targeted therapy can better control lupus symptoms.
This study tests an experimental daily pill (BI 3000202) for people with active lupus (SLE) to see if it can reduce disease activity. It compares different doses against a placebo, and you must already be on stable lupus background treatment.
Hear when a new SLE trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.